| Year |
Title |
Altmetric |
| 2020
|
Combining PARP and DNA-PK Inhibitors With Irradiation Inhibits HPV-Negative Head and Neck Cancer Squamous Carcinoma Growth.
Frontiers in Genetics.
11.
2020
|
|
| 2020
|
Metabolic checkpoints in neurodegenerative T helper 17 (TH17) and neuroregenerative regulatory T (Treg) cells as new therapeutic targets for multiple sclerosis.
Neural Regeneration Research.
15:267-269.
2020
|
|
| 2020
|
Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer.
PLoS ONE.
15.
2020
|
|
| 2020
|
Lipid microsphere bound oxycodone for pain management in patients receiving radiotherapy for head and neck cancer.
Supportive Care in Cancer.
2020
|
|
| 2020
|
The Top Concerns of Radiation Oncology Trainees in 2019: A Response from SCAROP
2020
|
|
| 2019
|
Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer.
Clinical Cancer Research.
25:7078-7088.
2019
|
|
| 2019
|
Differential escape mechanisms in cetuximab-resistant head and neck cancer cells.
Biochemical and Biophysical Research Communications.
517:36-42.
2019
|
|
| 2019
|
Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies.
Genes and Diseases.
6:232-246.
2019
|
|
| 2019
|
Gender, Professional Experiences, and Personal Characteristics of Academic Radiation Oncology Chairs: Data to Inform the Pipeline for the 21st Century
2019
|
|
| 2019
|
Myristoylated alanine-rich C-kinase substrate effector domain phosphorylation regulates the growth and radiation sensitization of glioblastoma.
International Journal of Oncology.
54:2039-2053.
2019
|
|
| 2019
|
A competing risk nomogram to predict severe late toxicity after modern re-irradiation for squamous carcinoma of the head and neck.
Oral Oncology.
90:80-86.
2019
|
|
| 2019
|
Treatment intensity in locoregionally advanced head and neck cancer: Recent investigation leads to new questions.
Translational cancer research.
8:S188-S194.
2019
|
|
| 2018
|
Bevacizumab-induced radiosenitzation in small cell lung cancer.
Annals of Oncology.
29:ix148.
2018
|
|
| 2018
|
In Regard to Bossi et al
2018
|
|
| 2018
|
Qualitative Assessment of Academic Radiation Oncology Department Chairs' Insights on Diversity, Equity, and Inclusion: Progress, Challenges, and Future Aspirations
2018
|
|
| 2018
|
A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer
2018
|
|
| 2018
|
Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative
2018
|
|
| 2018
|
Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis
2018
|
|
| 2018
|
ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage.
Journal of Biological Chemistry.
293:984-994.
2018
|
|
| 2017
|
Development and validation of nomograms predictive of overall and progression-free survival in patients with oropharyngeal cancer.
Journal of Clinical Oncology.
35:4057-4065.
2017
|
|
| 2017
|
Non-coding MIR491 is associated with less EGFr expression and greater radiosensitivity in human head and neck cancer cell lines.
Annals of Oncology.
28:x6.
2017
|
|
| 2017
|
Emotional Intelligence and Burnout in Academic Radiation Oncology Chairs.
Journal of Healthcare Management.
62:302-313.
2017
|
|
| 2017
|
p16, HPV, and cetuximab: What is the evidence?
2017
|
|
| 2017
|
In reply.
JAMA Otolaryngology-Head and Neck Surgery.
143:526.
2017
|
|
| 2017
|
Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522
2017
|
|
| 2016
|
Long-term results of a phase I/II trial of the addition of celecoxib to chemoradiotherapy for locally advanced or recurrent squamous cell carcinoma of the head-and-neck.
Journal of Radiation Oncology.
5:363-369.
2016
|
|
| 2016
|
Analysis of Predictive Factors for Acute Esophagitis in Lung Cancer Radiation Therapy.
2016
|
|
| 2016
|
Analysis of Predictive Factors for Pneumonitis in Lung Cancer Radiation Therapy.
2016
|
|
| 2016
|
Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial.
European journal of cancer.
64:1-11.
2016
|
|
| 2016
|
Cetuximab and radiotherapy in laryngeal preservation for cancers of the larynx and hypopharynx a secondary analysis of a randomized clinical trial.
JAMA Otolaryngology-Head and Neck Surgery.
142:842-849.
2016
|
|
| 2016
|
Management of Advanced Head and Neck Cancer.
New England Journal of Medicine.
375:492.
2016
|
|
| 2016
|
The authors reply.
New England Journal of Medicine.
375:492-493.
2016
|
|
| 2016
|
Correction: Kinomic profiling of electromagnetic navigational bronchoscopy specimens: A new approach for personalized medicine (PLoS ONE (2016) 9:12 (e116388) DOI: 10.1371/journal.pone.0116388).
PLoS ONE.
11.
2016
|
|
| 2016
|
Cetuximab or cisplatin as a radiosensitizer in locoregionally advanced head and neck cancer: Recent results.
Translational cancer research.
5:234-237.
2016
|
|
| 2016
|
Association of Human Papillomavirus and p16 Status with Outcomes in the IMCL-9815 Phase III Registration Trial for Patients with Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated with Radiotherapy with or Without Cetuximab.
Journal of Clinical Oncology.
34:1300-1308.
2016
|
|
| 2016
|
Difference in restricted mean survival time for cost-effectiveness analysis using individual patient data meta-analysis: Evidence from a case study.
PLoS ONE.
11.
2016
|
|
| 2015
|
Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 Inhibition.
BMC Cancer.
15.
2015
|
|
| 2015
|
Society of chairs of academic radiation oncology programs-endorsed radiation oncology department review process
2015
|
|
| 2015
|
Raising the next generation of physician-scientists: The chairs' perspective
2015
|
|
| 2015
|
DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma.
Oncotarget.
6:26995-27007.
2015
|
|
| 2015
|
Targeting the effector domain of the myristoylated alanine rich C-kinase substrate enhances lung cancer radiation sensitivity.
International Journal of Oncology.
46:1079-1088.
2015
|
|
| 2014
|
Kinomic profiling of electromagnetic navigational bronchoscopy specimens: A new approach for personalized medicine.
PLoS ONE.
9.
2014
|
|
| 2014
|
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.
Journal of Clinical Oncology.
32:2940-2950.
2014
|
|
| 2014
|
Pazopanib combined with radiation: In vivo model of interaction.
Cancer Biotherapy and Radiopharmaceuticals.
29:247-250.
2014
|
|
| 2014
|
Patterns of practice in radiation therapy for non-small cell lung cancer among members of the American Society for Radiation Oncology.
Practical Radiation Oncology.
4.
2014
|
|
| 2014
|
African Americans with oropharyngeal carcinoma have significantly poorer outcomes despite similar rates of human papillomavirus-mediated carcinogenesis.
Human Pathology.
45:310-319.
2014
|
|
| 2014
|
Burnout in United States academic chairs of radiation oncology programs
2014
|
|
| 2014
|
Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines.
Radiotherapy and Oncology.
111:468-474.
2014
|
|
| 2013
|
Stereotactic body radiation therapy (SBRT) for lung malignancies: Preliminary toxicity results using a flattening filter-free linear accelerator operating at 2400 monitor units per minute.
Radiation Oncology.
8.
2013
|
|
| 2013
|
Patterns of prophylactic gastrostomy tube placement in head and neck cancer patients: A consideration of the significance of social support and practice variation
2013
|
|
| 2013
|
Locoregional failure and the risk of distant metastasis after modern radiotherapy for head and neck cancer
2013
|
|
| 2013
|
Cost effectiveness of modified fractionation radiotherapy versus conventional radiotherapy for unresected non-small-cell lung cancer patients.
Journal of Thoracic Oncology.
8:1295-1307.
2013
|
|
| 2013
|
Flattening filter-free linac improves treatment delivery efficiency in stereotactic body radiation therapy.
Journal of Applied Clinical Medical Physics.
14:4126.
2013
|
|
| 2013
|
Flattening filter-free linac improves treatment delivery efficiency in stereotactic body radiation therapy.
Journal of Applied Clinical Medical Physics.
14:64-71.
2013
|
|
| 2012
|
Prognostic significance of thyroid or cricoid cartilage invasion in laryngeal or hypopharyngeal cancer treated with organ preserving strategies.
Radiation Oncology.
7.
2012
|
|
| 2012
|
HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair.
Cancer Research.
72:4796-4806.
2012
|
|
| 2012
|
Feasibility of exercising adults with asthma: a randomized pilot study
2012
|
|
| 2012
|
Hyperfractionated or accelerated radiotherapy in lung cancer: An individual patient data meta-analysis.
Journal of Clinical Oncology.
30:2788-2797.
2012
|
|
| 2012
|
Kinomic profiling approach identifies Trk as a novel radiation modulator.
Radiotherapy and Oncology.
103:380-387.
2012
|
|
| 2012
|
MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma.
Clinical Cancer Research.
18:3030-3041.
2012
|
|
| 2012
|
Gastrostomy tube placement and use in patients with head and neck cancer
2012
|
|
| 2012
|
Small-cell lung cancer: Prognostic factors and changing treatment over 15 years.
Clinical Lung Cancer.
13:115-122.
2012
|
|
| 2011
|
Impact of average weekly dose of radiation during radiotherapy alone or chemoradiotherapy in head and neck cancer
2011
|
|
| 2011
|
Examination of laryngoesophageal dysfunction-free survival as an endpoint in nonsurgical treatment of squamous cell carcinomas of the larynx and hypopharynx.
Cancer.
117:4447-4451.
2011
|
|
| 2011
|
Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation.
Radiotherapy and Oncology.
101:183-189.
2011
|
|
| 2011
|
Cetuximab augments cytotoxicity with poly (ADP-Ribose) polymerase inhibition in head and neck cancer.
PLoS ONE.
6.
2011
|
|
| 2011
|
Dosimetric impact of target definitions on normal structures in head and neck cancer.
Head and Neck Oncology.
3.
2011
|
|
| 2011
|
Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma.
Radiotherapy and Oncology.
99:339-343.
2011
|
|
| 2011
|
The poly(ADP-ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy.
Radiotherapy and Oncology.
99:331-338.
2011
|
|
| 2011
|
Prophylactic percutaneous endoscopic gastrostomy tube placement in treatment of head and neck cancer: A comprehensive review and call for evidence-based medicine.
Journal of Parenteral and Enteral Nutrition.
35:365-374.
2011
|
|
| 2011
|
Diagnosis-to-treatment interval and control of locoregionally advanced head and neck cancer
2011
|
|
| 2011
|
Dosimetric analysis of imaging changes following pulmonary stereotactic body radiation therapy
2011
|
|
| 2011
|
Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: Primary analysis of Radiation Therapy Oncology Group study RTOG 0214.
Journal of Clinical Oncology.
29:272-278.
2011
|
|
| 2011
|
Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: Neurocognitive and quality-of-life analysis.
Journal of Clinical Oncology.
29:279-286.
2011
|
|
| 2011
|
Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors..
Frontiers in Molecular Neuroscience.
4:47.
2011
|
|
| 2011
|
Wound healing following combined radiation and cetuximab therapy in head and neck cancer patients.
Journal of Wound Care.
20:166-170.
2011
|
|
| 2010
|
Comparison of Methods to Reduce Dose to Swallowing-Related Structures in Head and Neck Cancer
2010
|
|
| 2010
|
RapidArc Radiation Therapy: First Year Experience at the University of Alabama at Birmingham
2010
|
|
| 2010
|
Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy.
Journal of Medicinal Chemistry.
53:586-594.
2010
|
|
| 2010
|
Dosimetric Factors Associated With Long-Term Dysphagia After Definitive Radiotherapy for Squamous Cell Carcinoma of the Head and Neck
2010
|
|
| 2010
|
Margin on Gross Tumor Volume and Risk of Local Recurrence in Head-and-Neck Cancer
2010
|
|
| 2010
|
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
2010
|
|
| 2009
|
Inhibition of STAT-3 results in radiosensitization of human squamous cell carcinoma.
Radiotherapy and Oncology.
92:339-344.
2009
|
|
| 2009
|
Adjuvant radiotherapy for pancreatic cancer is associated with a survival benefit primarily in stage IIB patients.
Journal of Gastroenterology.
44:84-91.
2009
|
|
| 2009
|
Factors Associated With Long-Term Dysphagia After Definitive Radiotherapy for Locally Advanced Head-and-Neck Cancer
2009
|
|
| 2009
|
EGFR FISH as a predictive factor for selection of patients with non-small cell lung cancer treated with cetuximab and chemotherapy.
American Journal of Oncology Review.
8.
2009
|
|
| 2008
|
Locoregionally Advanced Head and Neck Cancer Treated With Primary Radiotherapy: A Comparison of the Addition of Cetuximab or Chemotherapy and the Impact of Protocol Treatment
2008
|
|
| 2008
|
Stage-specific survival differences associated with postoperative radiotherapy for gastrointestinal cancers.
Journal of Gastrointestinal Cancer.
39:86-99.
2008
|
|
| 2007
|
Is cetuximab active in patients with cisplatin-refractory squamous cell carcinoma of the head and neck?: Commentary.
Nature Clinical Practice Oncology.
4:690-691.
2007
|
|
| 2007
|
Design and development of water-soluble curcumin conjugates as potential anticancer agents.
Journal of Medicinal Chemistry.
50:6284-6288.
2007
|
|
| 2007
|
The authors reply [8].
New England Journal of Medicine.
357:2202-2203.
2007
|
|
| 2007
|
More on severe cutaneous reaction with radiotherapy and cetuximab [13].
New England Journal of Medicine.
357:1872-1873.
2007
|
|
| 2007
|
Biology of interactions: Antiepidermal growth factor receptor agents.
Journal of Clinical Oncology.
25:4057-4065.
2007
|
|
| 2007
|
Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53).
Journal of Clinical Oncology.
25:3124-3129.
2007
|
|
| 2007
|
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.
Journal of Clinical Oncology.
25:2191-2197.
2007
|
|
| 2007
|
A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734.
Clinical Lung Cancer.
8:268-272.
2007
|
|
| 2007
|
Clinical cancer advances 2006: Major research advances in cancer treatment, prevention, and screening - A report from the American Society of Clinical Oncology.
Journal of Clinical Oncology.
25:146-162.
2007
|
|
| 2006
|
Postoperative radiotherapy in non-small-cell lung cancer warrants further exploration in the era of adjuvant chemotherapy and conformal radiotherapy.
Journal of Clinical Oncology.
24:2978-2980.
2006
|
|
| 2006
|
The authors and a colleague reply [11].
New England Journal of Medicine.
354:2187.
2006
|
|
| 2006
|
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
New England Journal of Medicine.
354:567-578.
2006
|
|
| 2006
|
Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients.
Annals of Oncology.
17:473-483.
2006
|
|
| 2006
|
Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: A phase I study
2006
|
|
| 2005
|
Patterns of surgical care of lung cancer patients.
Annals of Thoracic Surgery.
80:2051-2056.
2005
|
|
| 2005
|
Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly.
Cancer.
103:2349-2354.
2005
|
|
| 2005
|
Limited-stage small-cell lung cancer (stages I-III): Observations from the National Cancer Data Base.
Clinical Lung Cancer.
6:355-360.
2005
|
|
| 2005
|
SU‐FF‐J‐123: Residual Tumor Motion in Respiratory Gated CT Treatment Planing.
Medical Physics.
32:1948.
2005
|
|
| 2004
|
Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.
Bioconjugate Chemistry.
15:1264-1274.
2004
|
|
| 2004
|
Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer
2004
|
|
| 2004
|
Radiosensitization by Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in in Vitro and in Vivo Human Cancer Models.
Clinical Cancer Research.
10:1263-1273.
2004
|
|
| 2004
|
Adenoviral vector-mediated augmentation of epidermal growth factor receptor (EGFr) enhances the radiosensitization properties of anti-EGFr treatment in prostate cancer cells
2004
|
|
| 2004
|
Anti-EGFR-mediated radiosensitization as a result of augmented EGFR expression
2004
|
|
| 2004
|
Quality of life in 650 lung cancer survivors 6 months to 4 years after diagnosis.
Mayo Clinic Proceedings.
79:1024-1030.
2004
|
|
| 2003
|
The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly.
Journal of Clinical Oncology.
21:3201-3206.
2003
|
|
| 2003
|
Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody.
Journal of Surgical Research.
111:274-283.
2003
|
|
| 2003
|
Intraoperative radiotherapy for head and neck and skull base cancer
2003
|
|
| 2003
|
Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.
Bioconjugate Chemistry.
14:302-310.
2003
|
|
| 2003
|
Validation of target volume and position in respiratory gated CT planning and treatment.
Medical Physics.
30:3196-3205.
2003
|
|
| 2002
|
Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation
2002
|
|
| 2002
|
Smoking behavior of 226 patients with diagnosis of stage IIIA/IIIB non-small cell lung cancer
2002
|
|
| 2002
|
Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer
2002
|
|
| 2002
|
Epidermal growth factor receptor as a therapeutic target in head and neck cancer..
Seminars in Radiation Oncology.
12:11-20.
2002
|
|
| 2002
|
A new graphic for quality adjusted life years (Q-TWiST) survival analysis: The Q-TWiST plot.
Quality of Life Research.
11:37-45.
2002
|
|
| 2002
|
Adjuvant radiation therapy after complete resection of non-small-cell lung cancer [3] (multiple letters).
Journal of Clinical Oncology.
20:1427-1429.
2002
|
|
| 2002
|
Model prediction of treatment planning for dose-fractionated radioimmunotherapy..
Cancer.
94:1264-1269.
2002
|
|
| 2002
|
A quality-adjusted reanalysis of a Phase III trial comparing once-daily thoracic radiation vs. twice-daily thoracic radiation in patients with limited-stage small-cell lung cancer
2002
|
|
| 2002
|
Effect of multileaf collimator leaf width on physical dose distributions in the treatment of CNS and head and neck neoplasms with intensity modulated radiation therapy.
Medical Physics.
29:1116-1119.
2002
|
|
| 2002
|
Epidermal growth factor receptor as a therapeutic target in head and neck cancer.
Seminars in Radiation Oncology.
12:11-20.
2002
|
|
| 2002
|
The possible use of uniform PORT doses is important in the SEER analysis, but undetected selection bias remains an issue.
Clinical Lung Cancer.
4:45-46.
2002
|
|
| 2001
|
Long-term results of a phase I/II study of high-dose thoracic radiotherapy with concomitant cisplatin and etoposide in limited stage small-cell lung cancer
2001
|
|
| 2001
|
Balancing the possible effectiveness of postoperative radiotherapy for non-small-cell lung cancer against the possible detriment of radiation-induced toxicity.
Journal of Clinical Oncology.
19:3905-3907.
2001
|
|
| 2001
|
Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.
Journal of Clinical Oncology.
19:3234-3243.
2001
|
|
| 2001
|
Commentary "effectiveness of therapy on non-small-cell lung cancer".
Clinical Lung Cancer.
2:191-192.
2001
|
|
| 2000
|
Sensitivity and action of etoposide on malignant glioma cell lines.
Cancer Radiothérapie.
4:57-64.
2000
|
|
| 2000
|
Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers..
Journal of Clinical Oncology.
18:47S-53S.
2000
|
|
| 2000
|
A prospective evaluation of the timing of postoperative radiotherapy for preventing heterotopic ossification following traumatic acetabular fractures
2000
|
|
| 2000
|
A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer
2000
|
|
| 2000
|
Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer.
Clinical Cancer Research.
6:597-601.
2000
|
|
| 2000
|
Non-small cell lung cancer: Introduction.
Seminars in Radiation Oncology.
10:263-266.
2000
|
|
| 2000
|
Point: The potential importance of elective nodal irradiation in the treatment of non-small cell lung cancer.
Seminars in Radiation Oncology.
10:308-314.
2000
|
|
| 2000
|
Postoperative irradiation in non-small cell lung cancer.
Seminars in Radiation Oncology.
10:280-288.
2000
|
|
| 2000
|
Unresectable or medically inoperable non-small cell lung cancer: The use of established clinical prognostic factors in making radiation-related treatment decisions.
Seminars in Radiation Oncology.
10:267-273.
2000
|
|
| 1999
|
Paclitaxel derivatives for targeted therapy of cancer: Toward the development of smart taxanes.
Journal of Medicinal Chemistry.
42:4919-4924.
1999
|
|
| 1999
|
Factors predicting patterns of recurrence after resection of N1 non- small cell lung carcinoma.
Annals of Thoracic Surgery.
68:1171-1176.
1999
|
|
| 1999
|
Frequency of noncontiguous lymph node involvement in patients with resectable nonsmall cell lung carcinoma.
Cancer.
86:1159-1164.
1999
|
|
| 1999
|
Frequency of noncontiguous lymph node involvement in patients with resectable nonsmall cell lung carcinoma..
Cancer.
86:1159-1164.
1999
|
|
| 1999
|
Patients with stage I non-small cell lung carcinoma at postoperative risk for local recurrence, distant metastasis, and death: Implications related to the design of clinical trials
1999
|
|
| 1999
|
Patterns of failure and overall survival in patients with completely resected T3 N0 M0 non-small cell lung cancer
1999
|
|
| 1999
|
The role of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma: Seeking to optimize local control and survival while minimizing toxicity.
Cancer.
86:195-196.
1999
|
|
| 1999
|
The role of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma: seeking to optimize local control and survival while minimizing toxicity..
Cancer.
86:195-196.
1999
|
|
| 1999
|
Predictors of subclinical nodal involvement in clinical stages I and II non-small cell lung cancer: Implications in the inoperable and three- dimensional dose-escalation settings
1999
|
|
| 1999
|
Combined modality therapy of A431 human epidermoid cancer using anti- EGFR antibody C225 and radiation.
Cancer Biotherapy and Radiopharmaceuticals.
14:451-463.
1999
|
|
| 1999
|
Current guidelines for the management of small cell lung cancer.
Mayo Clinic Proceedings.
74:809-816.
1999
|
|
| 1999
|
Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma.
Journal of Clinical Oncology.
17:2681-2691.
1999
|
|
| 1999
|
Sensitivity and action of etoposide on malignant glioma cell lines.
Cancer Radiothérapie.
3:57-64.
1999
|
|
| 1998
|
Ionizing radiation-induced MEK and Erk activation does not enhance survival of irradiated human squamous carcinoma cells
1998
|
|
| 1998
|
Impact of beam energy and field margin on penumbra at lung tumor-lung parenchyma interfaces
1998
|
|
| 1998
|
Adjuvant radiotherapy for squamous cell carcinoma of the tongue base: Improved local-regional disease control compared with surgery alone
1998
|
|
| 1998
|
The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma.
Cancer.
82:1037-1048.
1998
|
|
| 1998
|
The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study..
Cancer.
82:1037-1048.
1998
|
|
| 1998
|
Combined neck dissection and postoperative radiation therapy in the management of the high-risk neck: A matched-pair analysis
1998
|
|
| 1998
|
Spinal cord localization in the treatment of lung cancer: Use of radiographic landmarks
1998
|
|
| 1998
|
Bronchial carcinoid tumors: Importance of prognostic factors that influence patterns of recurrence and overall survival.
Radiology.
208:181-185.
1998
|
|
| 1997
|
Has radiotherapy become too expensive to be considered a treatment option for early glottic cancer?
1997
|
|
| 1997
|
Has radiotherapy become too expensive to be considered a treatment option for early glottic cancer?
1997
|
|
| 1997
|
Etoposide sensitivity of radioresistant human glioma cell lines.
Cancer Chemotherapy and Pharmacology.
41:93-97.
1997
|
|
| 1997
|
The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung carcinoma with ipsilateral mediastinal lymph node involvement.
Cancer.
80:1399-1408.
1997
|
|
| 1997
|
The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung carcinoma with ipsilateral mediastinal lymph node involvement..
Cancer.
80:1399-1408.
1997
|
|
| 1997
|
Utility of screening procedures for detecting recurrence of disease after complete response in patients with small cell lung carcinoma.
Cancer.
80:676-680.
1997
|
|
| 1997
|
Utility of screening procedures for detecting recurrence of disease after complete response in patients with small cell lung carcinoma..
Cancer.
80:676-680.
1997
|
|
| 1997
|
Laryngeal chondrosarcomas: The Mayo Clinic experience.
Journal of Surgical Oncology.
65:269-273.
1997
|
|
| 1997
|
Laryngeal chondrosarcomas: the Mayo Clinic experience..
Journal of Surgical Oncology.
65:269-273.
1997
|
|
| 1997
|
Postoperative localization of porta hepatis and abdominal vasculature in pancreatic malignancies: Implications for postoperative radiotherapy planning
1997
|
|
| 1997
|
Effectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer according to regression tree analyses of recurrence risks.
Annals of Thoracic Surgery.
64:1402-1407.
1997
|
|
| 1996
|
The significance of the sequence of administration of topotecan and etoposide.
Cancer Chemotherapy and Pharmacology.
39:109-112.
1996
|
|
| 1996
|
The interaction of buthionine sulphoximide (BSO) and the topoisomerase I inhibitor CPT-11..
The British journal of cancer. Supplement.
27.
1996
|
|
| 1996
|
Radiation therapy for glottic cancer using 6-MV photons.
Cancer.
77:381-386.
1996
|
|
| 1996
|
Radiation therapy for glottic cancer using 6-MV photons..
Cancer.
77:381-386.
1996
|
|
| 1996
|
Radiation therapy for glottic cancer using 6-MV photons [5].
Cancer.
78:183-183a.
1996
|
|
| 1996
|
The interaction of buthionine sulphoximide (BSO) and the topoisomerase I inhibitor CPT-11.
British Journal of Cancer.
74.
1996
|
|
| 1995
|
Long term results of a phase I/II study of aggressive chemotherapy and sequential upper and lower hemibody radiation for patients with extensive stage small cell lung cancer..
Cancer.
76:406-412.
1995
|
|
| 1995
|
Assessing the Interaction of Irradiation With Etoposide or Idarubicin.
Mayo Clinic Proceedings.
70:1053-1060.
1995
|
|
| 1995
|
Long term results of a phase I/II study of aggressive chemotherapy and sequential upper and lower hemibody radiation for patients with extensive stage small cell lung cancer.
Cancer.
76:406-412.
1995
|
|
| 1995
|
Management of stage ie primary gastric lymphoma.
Acta Haematologica.
94:59-68.
1995
|
|
| 1995
|
Prophylactic cranial irradiation in limited‐stage small cell lung cancer.
Cancer.
75:1302-1309.
1995
|
|
| 1994
|
Apoptosis occurs in lymphoma cells but not in hepatoma cells following ionizing radiation and photodynamic therapy.
Digestive Diseases and Sciences.
39:2467-2475.
1994
|
|
| 1994
|
The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities
1994
|
|
| 1994
|
Topoisomerase II-independent doxorubicin-induced cytotoxicity in an extremely doxorubicin-resistant cell line.
Biochemical and Biophysical Research Communications.
198:582-589.
1994
|
|
| 1994
|
Treatment of stage ie primary lymphoma of bone
1994
|
|
| 1994
|
Etoposide-resistance in the multidrug-resistant LZ-8 cells
1994
|
|
| 1994
|
Limited-stage small-cell lung cancer: Patterns of intrathoracic recurrence and the implications for thoracic radiotherapy.
Journal of Clinical Oncology.
12:496-502.
1994
|
|
| 1994
|
Postoperative adjuvant therapy for non-small cell lung cancer: a consensus report.
Lung Cancer.
11.
1994
|
|
| 1994
|
Pretreatment minimal staging for non-small cell lung cancer: an updated consensus report.
Lung Cancer.
11.
1994
|
|
| 1993
|
Malignant tracheoesophageal fistula in patients with esophageal cancer.
Cancer.
72:1513-1521.
1993
|
|
| 1993
|
Role of Radiation Therapy in the Management of Lung Cancer.
Mayo Clinic Proceedings.
68:593-602.
1993
|
|
| 1993
|
The interaction of etoposide with radiation: Variation in cytotoxicity with the sequence of treatment.
Life Sciences.
53.
1993
|
|
| 1992
|
Interaction of buthionine sulfoximine and the stabilization of DNA-topoisomerase II complexes by doxorubicin
1992
|
|
| 1990
|
Doxorubicin decreases the repair of radiation-induced DNA damage.
International Journal of Radiation Biology.
57:55-64.
1990
|
|
| 1989
|
Protection of doxorubicin cytotoxicity by cycloheximide
1989
|
|
| 1988
|
The management of vaginal melanoma.
Cancer.
62:2066-2072.
1988
|
|
